Login to Your Account

Visterra Makes Debut at ICAAC with Flu Antibody, Partnership

By Anette Breindl
Science Editor

Tuesday, September 11, 2012
The typical way to identify a broadly neutralizing antibody is to screen B cells for one, and then look for an epitope that can induce its production. Cambridge, Mass.-based start-up Visterra Inc. used a very different approach to come up with its VIS410, an antibody that is capable of neutralizing all strains of influenza A that the company has tested.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription